- Report
- March 2025
- 1048 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- June 2024
- 240 Pages
Global
From €2567EUR$2,700USD£2,156GBP
- Report
- March 2025
- 187 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- November 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- March 2025
- 193 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2021
- 397 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- February 2022
- 172 Pages
Global
From €2842EUR$2,990USD£2,388GBP
- Report
- July 2022
- 165 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- August 2024
- 82 Pages
Japan
From €3327EUR$3,500USD£2,795GBP
- Report
- April 2023
- 110 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2022
- 119 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- July 2023
- 210 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Book
- April 2018
- 312 Pages

Within the field of immune disorders drugs, cell-based immunotherapy represents a burgeoning area focused on harnessing and modifying immune cells to combat various immune-related conditions. This approach typically involves the manipulation of T cells, B cells, or dendritic cells, which are either isolated from a patient or generated de novo, then expanded, activated, or genetically engineered before being reintroduced into the patient's body. Such therapies aim to either bolster the immune response against pathogenic threats or to moderate an overactive immune system in cases of autoimmune diseases.
Cell-based immunotherapies have gained increasing attention due to their potential to offer targeted, personalized treatments. They encompass a range of techniques, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapies, tumor-infiltrating lymphocytes (TIL) therapy, and regulatory T-cell (Treg) therapy. While initially cell-based immunotherapies were primarily directed at treating cancer, their scope has expanded to address a variety of immune disorders such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis, and others, reflecting a novel frontier in immunological treatment strategies.
Companies that have ventured into the cell-based immunotherapy market include Novartis, Gilead Sciences through its subsidiary Kite Pharma, Bristol Myers Squibb following its acquisition of Celgene, Bluebird Bio, and Regeneron. These industry players are actively involved in the research, development, and commercialization of therapies that seek to Show Less Read more